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Virus-specific cytotoxic T lymphocytes (CTL) play a major role in the clearance of respiratory syncytial virus
(RSV) infection. We have generated cytotoxic T-cell clones (TCC) from two infants who had just recovered from
severe RSV infection. These TCC were functionally characterized and used to identify HLA class I (B57 and
C12)-restricted CTL epitopes of RSV.
Respiratory syncytial virus (RSV) is a common cause of
upper respiratory tract infections but may—especially in young
infants, the elderly, or immunocompromised individuals—
cause severe lower respiratory tract infections (12). In rodent
models, CD41, as well as CD81, RSV-specific T lymphocytes
proved to be involved in both recovery from and immune
pathogenesis of the infection (1, 2, 8, 19). Therefore, a fine
balance must exist in these models between protective and
disease-enhancing effects of virus-specific T lymphocytes.
RSV-specific CD81 cytotoxic T lymphocytes (CTL) against
virtually all RSV proteins have been demonstrated to circulate
in humans after RSV infection (4, 7, 9). CTL may be expected
to play a crucial role in the clearance of RSV infections, but
their role in protection and immune pathology remains un-
clear. Therefore, the identification of CTL epitopes of human
RSV may contribute to future studies concerning the role of
CTL in pathogenesis and protection from RSV infection. Here
we describe the functional characterization of CD81 cytotoxic
T-cell clones (TCC) generated from two infants who had just
recovered from severe RSV infection. These TCC were also
used to identify, for the first time, HLA class I-restricted CTL
epitopes of RSV.
Peripheral blood mononuclear cells (PBMC) were collected
from two infants 4 weeks after a severe, laboratory-confirmed
RSV infection. At the time of infection, they were 1 and 2
months old and had both been admitted to the intensive care
unit. B-lymphoblastic cell lines (B-LCL) were generated by
Epstein-Barr virus transformation (22), infected with RSV A2
(ATCC VR1322), and UV irradiated (24) to serve as autolo-
gous antigen-presenting cells (APC). PBMC (3 3 104/well in
96-well round-bottom plates) were stimulated with APC (104/
well) and expanded in RPMI 1640 medium supplemented with
antibiotics, 10% pooled and heat-inactivated human serum,
and recombinant human interleukin-2 (IL-2; 50 IU/ml). After
2 weeks, T cells were harvested and cloned by limiting dilution
using phytohemagglutinin stimulation as previously described
(25). TCC thus generated were expanded and tested for RSV
specificity by [3H]thymidine incorporation assays as previously
described (22). All of the RSV-specific TCC proved to be of
the CD81 phenotype in fluorescence-activated cell sorter anal-
ysis. TCC whose specificity for RSV was confirmed by a second
proliferation assay were tested for protein specificity by a
gamma interferon (IFN-g) ELIspot assay (Mabtech AB,
Stockholm, Sweden). In this test, paraformaldehyde-fixed au-
tologous B-LCL that had been infected with recombinant vac-
cinia viruses (rVV) expressing different RSV proteins (F, G, N,
P, M2, SH, M, 1B, or 1C) were used as APC. Briefly, TCC (5 3
103/well) were incubated with APC (104/well) for 4 h, trans-
ferred to anti-human IFN-g-coated plates, and incubated for
another 18 h. The ELIspot assay was further performed in
accordance with the kit manufacturer’s instructions. The results
are shown as numbers of IFN-g-producing cells (spots) per well.
Thirty-four RSV-specific TCC were generated from the
PBMC of patient 1, as detected in a [3H]thymidine incorpora-
tion assay. Of these, 27 proved to be RSV F specific and 7 were
RSV 1B specific in an IFN-g ELIspot assay (Fig. 1A). Twenty-
four RSV-specific TCC were generated from the PBMC of
patient 2 as detected by a [3H]thymidine incorporation assay.
Of these, 10 were RSV F specific and 14 proved to be RSV 1C
specific in an IFN-g ELIspot assay (Fig. 1B). None of the
clones detected by the [3H]thymidine incorporation assay was
found to be negative by the IFN-g ELIspot assay. Since the F
protein is considered to be a major CTL target (4, 7, 9), further
efforts were focused on the identification of CTL epitopes in
the F protein. To this end, 18-mer peptide amides overlapping
by 12 amino acids, together spanning the entire F protein of
RSV A2 (11, 18) (n 5 94), were generated in an automated
multiple-peptide synthesizer as previously described (26). The
purity of the peptides varied between 50 and 90%, as deter-
mined by analytical reverse-phase high-performance liquid
chromatography (C8 column; gradient of 0.1% trifluoroacetic
acid in water to 0.1% trifluoroacetic acid in acetonitrile). Au-
tologous B-LCL of patients 1 and 2 were pulsed overnight with
1 and 3 mM peptide, respectively. RSV F-specific TCC of
patient 1 reacted with peptides 17 and 18 (Fig. 2A). All of the
RSV F TCC of patient 2 reacted with peptide 91 and margin-
ally with peptide 90 (Fig. 2B). Subsequently, two additional
sets of partially overlapping 8- to 12-mer peptides (80 to 95%
purity) were generated to determine the respective minimal
epitopes. Autologous B-LCL of patients 1 and 2 were pulsed
for 1 h with the different peptides at 1 and 3 mM, respectively.
All of the RSV F-specific TCC of patient 1 reacted with one
nine-mer peptide (RARRELPRF) spanning residues 118 to
126 of the F protein (Fig. 2C). The RSV F TCC of patient 2 all
reacted with one nine-mer peptide (IAVGLLLYC) spanning
residues 551 to 559 of the F protein (Fig. 2D).
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FIG. 1. Responses of RSV-specific TCC from patients 1 (A) and 2 (B) measured by an IFN-g ELIspot assay using autologous B-LCL infected with RSV A2 or rVV
expressing the RSV F, 1B, or 1C protein. Results are indicated as numbers of spots per well. No responses against the B-LCL infected with the other rVV were found
(data not shown).
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The HLA restriction of the recognition by the RSV F TCC
was also determined by the IFN-g ELIspot assay using a set of
allogeneic B-LCL with partially matched HLA types loaded
with the respective minimal peptides, as shown in Fig. 3. Rec-
ognition of the RSV F epitope of patient 1 proved to be HLA
B57 restricted. Recognition of the epitope of patient 2 proved
to be C12 restricted.
Well-growing TCC of both specificities from each of the
FIG. 2. Fine mapping of T-cell epitopes on the RSV F protein. Responsiveness of TCC from patients 1 (A) and 2 (B) to partially overlapping 18-mer peptide amides
(n 5 94) spanning the F protein was measured by an IFN-g ELIspot assay. Minimal peptide activation of TCC from patients 1 (C) and 2 (D) was measured in an IFN-g
ELIspot assay using APC pulsed with two additional sets of overlapping 8- to 12-mer peptides. med, medium.
FIG. 3. Determination of HLA restriction of RSV F protein recognition by specific TCC using a set of autologous and partially HLA class I-matched B-LCL for
patients 1 (A) and 2 (B) by an IFN-g ELIspot assay.
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patients were arbitrarily selected and tested for cytotoxic ac-
tivity by a chromium release assay as previously described (23).
Briefly, autologous 51Cr-labeled, RSV-infected B-LCL and
control B-LCL or, in the case of the F-specific TCC of patient
2, minimal-peptide-loaded B-LCL and control B-LCL were
incubated with TCC for 4 h at 37°C at an effector-to-target cell
ratio of 10:1, which was found to be the most discriminative
ratio in preliminary experiments. Spontaneous 51Cr release
(target cells plus medium) and maximum 51Cr release (target
cells plus Triton X-100) were determined in 12 identical wells.
Supernatants were harvested and analyzed in a gamma
counter. Assay results were accepted only when the spontane-
ous-to-maximum release ratio was ,25%. All of the TCC
tested showed RSV-specific lysis (Fig. 4A). Virus-specific pro-
duction of cytokines in cell-free culture supernatant was mea-
sured as previously described (6). TCC were stimulated with
RSV-infected B-LCL or control B-LCL or, in the case of the
F-specific TCC of patient 2, with minimal-peptide-loaded B-
LCL or control B-LCL for 48 h. The concentrations of the
following cytokines were measured using commercially avail-
able sandwich enzyme-linked immunosorbent assay systems in
accordance with the manufacturers’ instructions: IL-4 (CLB,
Amsterdam, The Netherlands; detection limit, 7 pg/ml), IFN-g
(Medgenix Diagnostics, Fleurs, Belgium; detection limit, 25
pg/ml), IL-10 (Pharmingen, San Diego, Calif.; detection limit,
20 pg/ml). All of the TCC produced predominantly IFN-g,
indicating a type 1 phenotype in vitro (Fig. 4B).
In the present study, we identified two nine-mer CTL
epitopes on the RSV fusion protein. To our knowledge, these
are the first HLA class I-restricted CTL epitopes described for
RSV in humans. We found CTL epitopes with an HLA restric-
tion with a low prevalence in the population. But using the
techniques described here on samples of more children with a
recent RSV infection, CTL epitopes with more prevalent HLA
restrictions may be identified.
The TCC found in the children studied were all CD81 CTL
with a type 1-like cytokine profile. No RSV-specific CD41 T
cells were detected in the samples of these infants, while the
use of similar stimulation protocols did result in the identifi-
cation of such cells in other systems (14, 17, 20, 22). Virus-
specific CTL responses play a major role in the clearance of
RSV infections but may also be involved in pathogenesis (1, 3,
5, 8, 15). In mice, enhanced lung pathology induced by priming
with formalin-inactivated RSV has been associated with the
absence of a CTL response (13, 21). In young children, a CTL
response against RSV has been described but poor responses
were found in younger and more severely ill patients (10, 16).
The poor CTL response in young children has been suggested
to be one of the possible causes of more severe disease. In
these two patients, it was possible to detect RSV-specific cy-
totoxic TCC, showing that also in very young children with
clinically severe infections, priming of a CTL response does
occur, although we cannot say anything about the quantitative
responses.
In conclusion, use of the IFN-g ELIspot assay to determine
epitope specificity proved to be sensitive and convenient, since
only small numbers of T cells and APC were needed. This and
similar studies may be important for future studies concerning
FIG. 4. Cytotoxic responses (A) and cytokine production (B) of selected TCC with different protein specificities from patients 1 and 2. TCC were stimulated with
autologous RSV-infected or control B-LCL and in the case of the F-specific TCC of patient 2, minimal-peptide- or control (measles virus) peptide-loaded B-LCL.
Cytotoxic responses were measured in a chromium release assay using an effector-to-target cell ratio of 10. Cytokines in cell-free culture supernatant (IFN-g, IL-4, IL-5,
and IL-10) were measured by enzyme-linked immunosorbent assay. Levels of cytokines in the supernatant of TCC stimulated with control B-LCL were all below the
detection limit and are not shown.
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the role of CTL in the pathogenesis of RSV infection in chil-
dren.
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